Expansion of General Proximity's Clinical Advisor Board: Building on Our DMPK Expertise with Dr. Gondi Kumar
“Porem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.”
We are excited to announce that Gondi Kumar has joined General Proximity as an Advisor. Gondi brings over 30 years of extensive experience in pharmaceutical research and development, most recently serving as Senior Vice President of Nonclinical R&D at Bristol Myers Squibb (BMS).
In his role at BMS, Gondi led a team responsible for nonclinical safety assessment, drug metabolism, and pharmacokinetics, overseeing the entire R&D portfolio, including small molecules, biotherapeutics, and cell therapies. His previous leadership positions at Celgene, Abbott, and Amgen have further solidified his expertise in advancing product strategies and resolving scientific challenges.
Throughout his career, Gondi has played a pivotal role in the discovery and development of numerous therapeutic agents, including Norvir®, Kaletra®, and Otezla®. His leadership at BMS and previous positions at Celgene, Abbott, and Amgen have equipped him with a wealth of knowledge in nonclinical safety assessment, drug metabolism, and pharmacokinetics.
We look forward to leveraging Gondi’s wealth of knowledge and experience as he helps drive innovation at General Proximity. Please join us in welcoming him to our clincial advisory board!
